Both SPECT and PET imaging offer the potential for quantitative recovery of tissue radioactivity concentration over time and thus offer the possi bility of metabolic imaging based on estimates of biochemical reactions as predicted by mathematical models. Examples of such measurement ap proaches include the 2-[18F]fluoro-2-deoxyglucose (FDG) method for measurement of regional cere bral glucose utilization (Reivich et aI. , 1979) and the use of 150 for measurement of blood flow (Jones et aI. , 1976) and oxygen utilization (Frackowiak et aI. , 1980).
(FDG) method for measurement of regional cere bral glucose utilization (Reivich et aI. , 1979) and the use of 150 for measurement of blood flow (Jones et aI. , 1976) and oxygen utilization (Frackowiak et aI. , 1980) . As with any laboratory measurement, quantifica tion of an analyte in tissue or the rate of a physio logic or biochemical process is subject to both sys tematic and random errors of measurement. The following quality control terms are used to describe the "goodness" of any assay: "accuracy"-close ness to the "true value"; "precision" -reproduci bility of the same measurement made repetitively (this quality control parameter is often expressed as a mean measurement and a variance or standard deviation about the mean); "sensitivity"-the smallest difference between two measurements that can be reliably distinguished from "no difference. " In any assay system, precision is often more im portant than accuracy because of the common practice, which is often used in PET and SPECT imaging, of comparing a given response in a subject or patient with those of a "normal population. " Moreover, the sensitivity of the measurement is also a function of the precision of measurement as well as the imaging physics of the situation.
These applications of functional imaging, in order to be quantitatively accurate, depend on scrupulous attention to quality control of the major processes that make up an imaging study: radiopharmaceu tical production, laboratory analyte measurement, and operation of the imaging instrument itself. This process will be illustrated with PET imaging as the principal focus. and Buckingham, 1975; Compound Index, 1986; Comar et aI. , 1982; Fowler and Wolf, 1982; Reivich and Alavi, 1985; Phelps et aI. , 1986) . Stringent quality control requirements must be observed if meaningful and comparable results are to be forth coming. These include identification of radionu clidic and chemical and radiochemical impurities and determination of specific activities as well as apyrogenicity and sterility of the final product.
Detailed quality control procedures may be ob tained from recent review articles (Welch, 1977; Kristensen, 1979) . Continued attention to quality control is imperative during the production of any radiopharmaceutical. Recent experience with 150 and 18F production for incorporation into com monly used radiopharmaceuticals is cited to illus trate these points.
Classically, 150 is produced by the reaction of deuterons on nitrogen gas containing a specific concentration of oxygen scavenger. However, for centers restricted to proton irradiations, the use of an oxygen gas target initially for the preparation of CI502 and subsequently modified to produce H2150 has been reported (Beaver et aI. , 1976; Fernandez Rubio et aI. , 1981) . The radionuclide purity of the pharmaceutical gaseous product was indicated at 99.8% end of bombardment (EOB) with 13N as the impurity. In the course of utilizing this target system to prepare 150-labeled oxygen, gamma spectrometry analysis of the final pharmaceutical indicated a trace impurity (0. 1%) of llC. Although not seemingly a large concentration, the clinical ap plication of the 150 product combined with the ASSESSMENT OF FUNCTIONAL IMAGING S9 short half-life of oxygen required that the impurity be eliminated. The impurity was identified as CO2, and presumably arose from an oxidative radiolysis of the initial product from the interaction of protons with a trace concentration of nitrogen present in the oxygen target gas. This contaminant is removed from the final 150 gas by passage through a solid basic trap in an "on-line" process.
18F can be prepared by numerous nuclear reac tions, including the deuteron irradiation of neon gas or proton reactions on enriched 180 targets. The deuterons on neon reaction was the most widely applied to produce 18F for incorporation into FDG (Ido et aI., 1977) . Although quality control methods initially indicated isomerically pure FDG could be derived from this method, recent experimental evi dence indicates radiochemical impurities, including 2-fluoro-2-deoxY-D-mannose. As much as 15% is typically present in some preparations (Bida et aI., 1984a,b; Herscheid et aI., 1984; Jewett et aI., 1984; Shiue et ai., 1985) .
A more specific fluorination reaction has been reported, which is said to yield FDG in 98.3% ra diochemical purity (Vora et aI., 1986) . Further study is required before the presence of a fluori nated altrose can be excluded, however.
Thus, the necessity of research-oriented facilities to prepare effective and uniform radiolabeled products following good manufacturing practices is undeniable. Careful consideration must be given to the analytical methodology to ensure that the product is of uniform quality for each formulation and to provide clinical results that are reproducible and definitive.
LABORATORY ANALYTE MEASUREMENTS
Many of the methods used to measure a bio chemical process in vitro with PET or SPECT imaging will depend on a corresponding assessment of the concentration of the nonradioactive analyte in the tissues of the patient. For example, the FDG method of measuring regional cerebral glucose me tabolism depends on the glucose concentration in arterial blood as one input parameter. Careful at tention to the details of quality control is beyond the scope of this review, but numerous outstanding programs of quality assurance are available, and the research laboratory that measures its own glu cose values would do well to consult with the clin ical pathologist at the institution and obtain a copy of the College of American Pathology survey ques tionnaire to make sure that good laboratory prac tices are being followed in the assay of glucose.
Similarly, gamma well counting also is a neces sity for obtaining the time-activity curve of tracer disappearance from the blood. Standard elements of quality control must be applied to the gamma counter on a routine basis. These include logging background counts as a function of time and re cording the repetitive counting of radioactive stan dards to ensure that no drift has occurred in the energy discrimination of counting circuits. Again, referral to the College of American Pathology pro gram in nuclear medicine is recommended.
PET IMAGING PROCEDURE
Numerous reviews have dealt with the problems of imaging physics that are important determinants of quantification of PET imaging. To assist in con trolling machine-related problems in PET or SPECT measurements, we recommend using the concept of the "control chart." The concept is to record a calibration parameter, which is most rep resentative of the overall function of the measure ment system, and to plot the data as shown in Fig. 1 as a function of time. The example shown is the "K*CAL" parameter of the PET device, which re lates the measurement of a given quantity of radio activity in the PET device to the same measure ment obtained in the gamma counter. A plot of this parameter as a function of scanning day shows that there has been a considerable variation in the mea surement, which has gotten less and less as time has gone by. This parameter varies by � 10% at present, whereas variation at the start of the as sessment period was nearly three times this amount, indicating a much larger swing in the counting capabilities of the overall measurement system. Such a control chart is usually set up so
:,m m ' ''' ' '�.�'' :��:�''i-'3t � � 'm I that a group of 20 individual runs is used to com pute means and standard deviations about the means as an index of the day-to-day variability for the interval of measurement. A new mean and stan dard deviation are then computed for the next 20 measurements and so on, and in this way the vari ance as a function of time is assessed. In addition, any value that lies outside 2 SDs is scrutinized (ac tually, 1 value in 20 will lie outside this line) above or below the ± 2-SD envelope. Any value that is particularly far away, such as the value of day 69, is an indication that there may be a problem some where in the measurement system and requires fur ther evaluation to determine whether or not all components, i.e., gamma counter, imaging device, aliquoting of standard into phantom, etc., are accu rate.
Specific recommendations

Prior to scan
Weekly normalization of scanners should be conducted to check the detector efficiency. When the isotope arrives, there should be one person to inject, one to take down sample times, and one to draw the blood. Once the patient is injected, the signal is given, start time is recorded, and running time is started.
The timing device should be synchronized with that of the computer used in collecting the data.
After the scan
The arterial and intravenous lines should be removed and the patient should slowly return to a sitting position. When properly reor iented the patient should be escorted to the restroom and instructed to void to eliminate as much residual radioactivity as possible.
Postscan interviewing is useful.
As with any valuable stored data, scan data should be backed up and stored as soon as possible, especially if postscan processing will be taking place at a later time. Clear and con cise notes concerning any abnormalities in procedure may prove invaluable later and should be kept with the patient's files.
